Mylan claimed the patent didn’t cover a new invention, and filed a petition for review after Bayer and partner Johnson & Johnson sued to prevent Mylan from selling a generic version of the drug. The US Patent Trial and Appeal Board has ruled against Roche in its attempts to force a patent trial of Bayer 's blood clot disorder patent . It had argued that the patent did not concern a new drug and had launched the trial after it was prevented from developing a generic version by a joint patent and J&J suit .
The US Patent Trial and Appeal Board has ruled against Roche in its attempts to force a patent trial of Bayer 's blood clot disorder patent . It had argued that the patent did not concern a new drug and had launched the trial after it was prevented from developing a generic version by a joint patent and J&J suit .